Opzelura cream is a topically applied JAK inhibitor indicated for the treatment of atopic dermatitis and for nonsegmental vitiligo in patients over the age of 12. The package insert contains the same boxed warnings that have been applied to oral JAK inhibitors and include warnings about malignancy, major adverse cardiovascular events, thrombosis, serious infections, and death; but there is no evidence that these are increased with topical application of Opzelura cream.  The package insert recommends against using in combination with biologics, other JAK inhibitors, or immunosuppressive drugs such as azathioprine and cyclosporine; but in clinical practice, Opzelura cream is often used in combination with other treatments for atopic dermatitis such as biologic therapies.

Learn more about Opzelura

Latest research

large_Opzelura image.jpeg

medium_Opzelura image.jpeg

small_Opzelura image.jpeg

thumbnail_Opzelura image.jpeg

Opzelura image.jpeg

Opzelura (ruxolitinib) cream 1.5%

Taltz (ixekizumab) is a monoclonal antibody biologic therapy administered by subcutaneous injection indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients aged 6 years and older, adults with active psoriatic disease, adults with active ankylosing spondylitis, and adults with active nonradiographic axial spondyloarthritis with objective signs of inflammation. It targets interleukin 17A, a cytokine involved in the inflammatory process of psoriasis, helping to reduce symptoms and achieve clearer skin. The package insert specifically mentions the following adverse events: injection site reaction, upper respiratory infections, nausea, and tinea infection. It is recommended to avoid combining Taltz with other immunosuppressive therapies such as other biologics or live vaccines. Taltz can be used as part of a broader treatment strategy for psoriasis, often used alongside topical or other systemic therapies to optimize patient outcomes, and is a safe and effective long-term therapy option for the treatment of psoriasis in both adults and children. 

Learn more about Taltz

small_taltz_1.jpg

thumbnail_taltz_1.jpg

taltz_1.jpg

Taltz (ixekizumab) 

small_DermToolkitLogoCropped.png

thumbnail_DermToolkitLogoCropped.png

DermToolkitLogoCropped.png

The most up-to-date information, quick reference charts, and essential tools for HCPs by HCPs.

Level up your practice with our new

Del Rosso-Armstrong-Lebwohl-Brownstone

Download our free Quick Reference Chart for Topical Non-steroidal and Fixed Combination Therapies

Topical Non-steroidal Chart icon.png

Topical Non-steroidal Therapies

Brownstone-Lebwohl

Download our free biologics for dermatology Quick Reference Charts

Biologics Chart icon.png

Biologic Medications for Psoriasis and Atopic Dermatitis

by Dr. Mark Lebwohl

Check out our free Generalized Idiopathic Pruritus Questionnaire

Generalized Idiopathic Pruritus Questionnaire icon.png

Generalized Idiopathic Pruritus Questionnaire

Download our free Quick Reference Chart for Vaccines and Systemic Therapies Chart